Insider Buying at MIRA Pharmaceuticals as Matthew Del Giudice Acquires Shares

Matthew Del Giudice, an insider at MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA), purchased 50,000 shares of the company on June 12, 2026. This transaction comes as the stock is trading near $0.93. The purchase highlights insider interest in the company's future prospects.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

On June 12, 2026, several insiders, including Matthew Del Giudice, Edward Clouston Macpherson, Matthew Pratt Whalen, and Denil Nanji Shekhat, each bought 50,000 shares of MIRA Pharmaceuticals. These transactions were not part of a pre-planned trading scheme. Earlier, on December 17, 2025, CEO Erez Aminov acquired 3,155,170 shares, indicating strong insider confidence in the company's direction.

Other Institutional Activity in MIRA Pharmaceuticals

Vanguard Capital Management LLC increased its position in MIRA Pharmaceuticals by acquiring 693,912 shares, bringing its total to 693,912 shares, valued at approximately $742,486. Geode Capital Management, LLC also boosted its holdings, adding 18,012 shares to end with 290,890 shares worth about $311,251. In contrast, Suncoast Equity Management reduced its position by 12,644 shares, leaving it with 90,645 shares valued at $96,990.

MIRA Pharmaceuticals Stock Snapshot

Shares of NasdaqCM:MIRA traded around $0.93 recently. The company has a market cap of approximately $39.2 million. MIRA Pharmaceuticals is not currently profitable, thus it has no meaningful P/E ratio. The stock's 52-week range is between $0.90 and $2.45, with a 50-day moving average of $1.02 and a 200-day moving average of $1.28. The firm's current ratio is exceptionally high at 82.16, which indicates strong liquidity.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc. is a healthcare company based in Miami, Florida, focusing on developing treatments for neurological and neuropsychiatric disorders. The company is working on several pre-clinical and clinical-stage products, including Ketamir-2, an NMDA receptor modulator, and MIRA-55, an investigational treatment for anxiety and cognitive decline. Led by CEO Erez Aminov, MIRA Pharmaceuticals aims to advance its pipeline to address unmet medical needs in neuroscience.

Bottom Line

Insider buying activity at MIRA Pharmaceuticals, particularly by key figures like CEO Erez Aminov and other insiders, suggests confidence in the company's future. While the latest 13F filings provide a historical snapshot, these insider transactions may offer insights into potential future developments. Investors often watch such moves closely, as they can signal insiders' expectations for the company's performance.